How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

68,033 results for

Neurology Links

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

101. Low Serum Kallistatin Level was Associated with Poor Neurological Outcome of Out-of-Hospital Cardiac Arrest Survivors: Proteomics study. (PubMed)

Low Serum Kallistatin Level was Associated with Poor Neurological Outcome of Out-of-Hospital Cardiac Arrest Survivors: Proteomics study. To identify proteins of which depletion are associated with the poor 6-month neurological outcome of out-of-hospital cardiac arrest survivors.Seven healthy volunteers and 34 out-of-hospital cardiac arrest survivors admitted to the intensive care unit (ICU) and underwent targeted-temperature management were enrolled. According to the 6-month cerebral (...) and poor outcome groups (>2-fold change) and excluded 5 proteins related to haemolysis or remaining high abundant proteins. To confirm the 2 identified proteins: retinal dehydrogenase 1 and Kallistatin, we performed enzyme-linked immunosorbent assay with individual serum. Finally, old age (odds ratio = 1.055; 95% confidence interval, 1.002-1.112; p = 0.043) and low serum kallistatin level at 0 h (odds ratio = 0.784; 95% confidence interval, 0.618-0.995; p = 0.046) were independently associated

2018 Resuscitation

102. Cerebral embolization during endovascular infrarenal, juxtarenal, and suprarenal aortic aneurysm repair, high-risk maneuvers, and associated neurologic outcomes. (PubMed)

invasive manipulation of wires and cannulas within the aorta, but research into cerebral emboli during aortic aneurysm repair and cognitive or neurologic injury is scarce and limited to thoracic aneurysms. This study prospectively studied embolic phenomena detected in the middle cerebral artery during infrarenal, juxtarenal, and thoracic endovascular aortic repair (TEVAR) and investigated links to delirium, stroke, and postoperative cognitive decline.There were 60 patients who received continuous left (...) Cerebral embolization during endovascular infrarenal, juxtarenal, and suprarenal aortic aneurysm repair, high-risk maneuvers, and associated neurologic outcomes. Risk factors for postoperative cognitive decline after noncardiac surgery are multifactorial and poorly understood. Evidence suggests that perioperative microembolic damage to the brain on movement of wires and catheters during endovascular aortic procedures may play an important role. Endovascular aortic aneurysm repair requires

2018 Journal of Vascular Surgery

103. Ginkgolide With Intravenous Alteplase Thrombolysis in Acute Ischemic Stroke Neurological Improving Trial

Ginkgolide With Intravenous Alteplase Thrombolysis in Acute Ischemic Stroke Neurological Improving Trial Ginkgolide With Intravenous Alteplase Thrombolysis in Acute Ischemic Stroke Neurological Improving Trial - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100 (...) ). Please remove one or more studies before adding more. Ginkgolide With Intravenous Alteplase Thrombolysis in Acute Ischemic Stroke Neurological Improving Trial (GIANT) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier

2018 Clinical Trials

104. Brain Stimulation for Neurological Patients

: Double (Participant, Outcomes Assessor) Primary Purpose: Treatment Official Title: Brain Stimulation for Neurological Patients Actual Study Start Date : January 24, 2017 Estimated Primary Completion Date : January 1, 2020 Estimated Study Completion Date : January 1, 2020 Resource links provided by the National Library of Medicine related topics: related topics: resources: Arms and Interventions Go to Arm Intervention/treatment Experimental: Group A NEUROLITH Cycle 1: Active treatment Cycle 2: Sham (...) Brain Stimulation for Neurological Patients Brain Stimulation for Neurological Patients - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Brain Stimulation for Neurological Patients The safety and scientific

2018 Clinical Trials

105. Practice guideline update summary: Efficacy and tolerability of the new antiepileptic drugs I: Treatment of new-onset epilepsy: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology and th (PubMed)

Practice guideline update summary: Efficacy and tolerability of the new antiepileptic drugs I: Treatment of new-onset epilepsy: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology and th To update the 2004 American Academy of Neurology (AAN) guideline for treating new-onset focal or generalized epilepsy with second- and third-generation antiepileptic drugs (AEDs).The 2004 AAN criteria were used to systematically review (...) literature (January 2003-November 2015), classify pertinent studies according to the therapeutic rating scheme, and link recommendations to evidence strength.Several second-generation AEDs are effective for new-onset focal epilepsy. Data are lacking on efficacy in new-onset generalized tonic-clonic seizures, juvenile myoclonic epilepsy, or juvenile absence epilepsy, and on efficacy of third-generation AEDs in new-onset epilepsy.Lamotrigine (LTG) should (Level B) and levetiracetam (LEV) and zonisamide

2018 Neurology

106. Practice guideline update summary: Efficacy and tolerability of the new antiepileptic drugs II: Treatment-resistant epilepsy: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology and the (PubMed)

Practice guideline update summary: Efficacy and tolerability of the new antiepileptic drugs II: Treatment-resistant epilepsy: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology and the To update the 2004 American Academy of Neurology guideline for managing treatment-resistant (TR) epilepsy with second- and third-generation antiepileptic drugs (AEDs).2004 criteria were used to systemically review literature (January 2003 (...) to November 2015), classify pertinent studies according to the therapeutic rating scheme, and link recommendations to evidence strength.Forty-two articles were included.The following are established as effective to reduce seizure frequency (Level A): immediate-release pregabalin and perampanel for TR adult focal epilepsy (TRAFE); vigabatrin for TRAFE (not first-line treatment); rufinamide for Lennox-Gastaut syndrome (LGS) (add-on therapy). The following should be considered to decrease seizure frequency

2018 Neurology

107. Neurologic and cognitive outcomes associated with the clinical use of xenon: a systematic review and meta-analysis of randomized-controlled trials. (PubMed)

that xenon may be associated with better neurologic outcomes compared with the standard of care therapy in certain specific clinical situations. More clinical trials are needed to determine any potential benefit linked to xenon administration. (...) Neurologic and cognitive outcomes associated with the clinical use of xenon: a systematic review and meta-analysis of randomized-controlled trials. Xenon has been shown to have positive neurologic effects in various pre-clinical models. This study systematically reviewed the randomized-controlled trials (RCTs) investigating neurologic and cognitive outcomes associated with the clinical use of xenon.We searched PubMed, CENTRAL, EMBASE, CINAHL, elibrary.ru (for Russian studies), Google Scholar

2018 Canadian Journal Of Anaesthesia

108. Psychomotor developmental disorders: a link to antidepressants?

Psychomotor developmental disorders: a link to antidepressants? Prescrire IN ENGLISH - Spotlight: Archive ''Psychomotor developmental disorders: a link to antidepressants?'', 1 February 2013 {1} {1} {1} | | > > > Psychomotor developmental disorders: a link to antidepressants? Spotlight: Archives Every month, the subjects in Prescrire’s Spotlight. 2013 :  |   |  Spotlight Archives Psychomotor developmental disorders: a link to antidepressants? It is best to avoid prescribing SSRI (...) of malformation, especially cardiac, after exposure in early pregnancy. Other studies also suggest a risk to the infant’s neurological development. One study has shown a significant delay in psychomotor development in infants aged 6 to 40 months who have been exposed to SSRI antidepressants in the womb. Findings from other studies have been more reassuring. However, the overall results are not convincing. Above all it is clear that not enough is known about the long-term and potentially severe consequences

2014 Prescrire

109. Succinate links atrial dysfunction and cardioembolic stroke. (PubMed)

underlying link between CE stroke and energy metabolism.© 2019 American Academy of Neurology. (...) Succinate links atrial dysfunction and cardioembolic stroke. To determine whether altered metabolic profiles represent a link between atrial dysfunction and cardioembolic (CE) stroke, and thus whether underlying dysfunctional atrial substrate may contribute to thromboembolism risk in CE stroke.A total of 144 metabolites were measured using liquid chromatography-tandem mass spectrometry in plasma samples collected within 9 hours of stroke onset in 367 acute stroke patients. Stroke subtype

2019 Neurology

110. Levodopa-induced dyskinesia is closely linked to progression of frontal dysfunction in PD. (PubMed)

Levodopa-induced dyskinesia is closely linked to progression of frontal dysfunction in PD. To assess the relationship between the development of levodopa-induced dyskinesia (LID) and longitudinal changes in cognition.In this retrospective cohort study, we recruited 119 patients with Parkinson disease (PD) who underwent baseline and follow-up neuropsychological evaluations and were treated with levodopa for >5 years. On the basis of LID development, the patients were classified as patients (...) ) in the PD-LID- group.These results demonstrated that LID was closely associated with the progression of cognitive decline, especially frontal executive dysfunction, and the development of PD dementia.© 2019 American Academy of Neurology.

2019 Neurology

111. Headache: an important symptom possibly linked to white matter lesions in thalassaemia. (PubMed)

Headache: an important symptom possibly linked to white matter lesions in thalassaemia. Neurological manifestations are reported only occasionally in patients with thalassaemia and are given much less prominence than the complications related to anaemia and iron overload. White matter changes (WMCs) on magnetic resonance imaging (MRI) in patients with thalassaemia were first reported two decades ago but the significance of these lesions remains unclear. We studied the neurological and cognitive

2019 British journal of haematology

112. Weight loss and improved mood after aerobic exercise training are linked to lower plasma anandamide in healthy people. (PubMed)

Weight loss and improved mood after aerobic exercise training are linked to lower plasma anandamide in healthy people. Anandamide, a major endocannabinoid, participates in energy metabolism homeostasis and neurobehavioral processes. In a secondary analysis of an open-label, randomized controlled trial, we investigated the long-term effect of aerobic exercise on resting plasma anandamide, and explored its relationship with changes in body weight, cardiorespiratory fitness, and mood status (...) in healthy, physically inactive individuals. Participants recruited between March 2013 to August 2015 at the UNIFESP's Neurology/Psychobiology Department were randomly allocated into a 12-weeks supervised moderate exercise program, or into waitlist, control condition. Thirty-four participants (age = 38 ± 11.5, BMI = 26.6 ± 3.6) were intention to treat-analysed (Exercise: n = 17; Control: n = 17). After intervention, there were significant decreases in plasma anandamide (p < .01), anger, anxiety, and body

2019 Physiology & behavior

113. Emerging links between pediatric lysosomal storage diseases and adult parkinsonism. (PubMed)

role of lysosomes in neuronal homeostasis, neurological manifestations, including movement disorders, can accompany many lysosomal storage disorders. Over the last decade, evidence from genetics, clinical epidemiology, cell biology, and biochemistry have converged to implicate links between lysosomal storage disorders and adult-onset movement disorders. The strongest evidence comes from mutations in Glucocerebrosidase, which cause Gaucher's disease and are among the most common and potent risk (...) Emerging links between pediatric lysosomal storage diseases and adult parkinsonism. Lysosomal storage disorders comprise a clinically heterogeneous group of autosomal-recessive or X-linked genetic syndromes caused by disruption of lysosomal biogenesis or function resulting in accumulation of nondegraded substrates. Although lysosomal storage disorders are diagnosed predominantly in children, many show variable expressivity with clinical presentations possible later in life. Given the important

2019 Movement Disorders

114. Tumor-infiltrating T-cell Receptor-beta Repertoires are Linked to the Risk of Late Chemoradiation-induced Temporal Lobe Necrosis in Locally Advanced Nasopharyngeal Carcinoma. (PubMed)

Tumor-infiltrating T-cell Receptor-beta Repertoires are Linked to the Risk of Late Chemoradiation-induced Temporal Lobe Necrosis in Locally Advanced Nasopharyngeal Carcinoma. Temporal lobe necrosis (TLN), a late complication of nasopharyngeal carcinoma (NPC) after concurrent chemoradiotherapy (CCRT), causes permanent neurologic deficits. We aimed to investigate the risk factors for the development of CCRT-induced TLN in locally advanced NPC patients.The incidence of CCRT-induced TLN (...)  < .0001). We found that in the T4 NPC patients, univariate and multivariate analyses showed the radiation tolerance dose-volume effect was not an absolutely independent factor influencing TLN occurrence. However, increased TLN risk was observed in association with higher pre-CCRT baseline and post-CCRT neutrophil-to-lymphocyte ratios. There was also a link between intratumoral TCRbeta repertoire subtypes and TLN incidence. Combining the inherent TCRbeta genomic susceptibility with the clinical

2019 Biology and Physics

115. X-linked myotubular myopathy: A prospective international natural history study. (PubMed)

X-linked myotubular myopathy: A prospective international natural history study. Because X-linked myotubular myopathy (XLMTM) is a rare neuromuscular disease caused by mutations in the MTM1 gene with a large phenotypic heterogeneity, to ensure clinical trial readiness, it was mandatory to better quantify disease burden and determine best outcome measures.We designed an international prospective and longitudinal natural history study in patients with XLMTM and assessed muscle strength and motor (...) neutralizing activity was detected in 26% with 2 patients having an inhibitory titer >1:10.Our data confirm that XLMTM is slowly progressive for male survivors regardless of their phenotype and provide outcome validation and natural history data that can support clinical development in this population.NCT02057705.© 2019 American Academy of Neurology.

2019 Neurology

116. MRI brain lesions in asymptomatic boys with X-linked adrenoleukodystrophy. (PubMed)

MRI brain lesions in asymptomatic boys with X-linked adrenoleukodystrophy. To describe the brain MRI findings in asymptomatic patients with childhood cerebral adrenoleukodystrophy (CCALD).We retrospectively reviewed a series of biochemically or genetically confirmed cases of adrenoleukodystrophy followed at our institution between 2001 and 2015. We identified and analyzed 219 brain MRIs from 47 asymptomatic boys (median age 6.0 years). Patient age, MRI scan, and brain lesion characteristics (...) patients (r = -0.745; p < 0.0001). Older patients (median age 14.4 y/o) tended to undergo spontaneous arrest of disease. Early lesions grew 46× faster when still limited to the splenium, genu of the corpus callosum, or the brainstem (p = 0.001).We provide a description of CCALD lesion development in a cohort of asymptomatic boys. Understanding the early stages of CCALD is crucial to optimize treatments for children diagnosed by newborn screening.© 2019 American Academy of Neurology.

2019 Neurology

117. Exploring causal pathways linking cerebral small vessel diseases burden to poststroke depressive symptoms with structural equation model analysis. (PubMed)

Exploring causal pathways linking cerebral small vessel diseases burden to poststroke depressive symptoms with structural equation model analysis. Cerebral small vessel diseases (SVD) are associated with poststroke depressive symptoms (PDS). The mechanisms underlying the association between SVD burden and PDS are unclear. This study investigated the clinical pathways linking SVD burden to PDS.A cohort of 563 patients with acute ischemic stroke were examined at three and fifteen months after (...) all four SVD markers in structural equation modeling (SEM). SEM was further employed to examine the direct and indirect linking pathways between SVD burden, infarct volumes, stroke severity, poststroke cognitive and physical dysfunctions, and PDS.The latent SVD burden was directly associated with more severe PDS at the 3-month follow-up (path coefficient=0.11), while SVD burden and PDS at the 15-month were mainly linked through PDS at the 3-month follow-up (path coefficient=0.48). The volume

2019 Journal of Affective Disorders

118. Burosumab (Crysvita) - X-linked hypophosphataemia/hypophosphatemia

Burosumab (Crysvita) - X-linked hypophosphataemia/hypophosphatemia 30 Churchill Place ? Canary Wharf ? London E14 5EU ? United Kingdom An agency of the European Union Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5520 Send a question via our website www.ema.europa.eu/contact 14 December 2017 EMA/148319/2018 Committee for Medicinal Products for Human Use (CHMP) Assessment report Crysvita International non-proprietary name: burosumab Procedure No. EMEA/H/C/004275/0000 Note Assessment (...) Questionnaire CHO Chinese Hamster Ovary Cl chloride CKD Chronic kidney disease CL Clearance CL/F Clearance/bioavailability CLBA competitive ligand-binding assay CLss/F clearance at steady state/bioavailability Conc. concentration CPV Continued Process Verification CQA Critical Quality Attribute CrCL creatinine clearance CRT Controlled Room Temperature CT Computerized Tomography CTx carboxy-terminal cross-linked telopeptide of collagen type I CV Coefficient of Variation DHFR Dihydrofolate Reductase DLT dose

2018 European Medicines Agency - EPARs

119. Corneal cross-linking for keratoconus caused by compulsive eye rubbing in patients with Tourette syndrome: Three case reports. (PubMed)

Corneal cross-linking for keratoconus caused by compulsive eye rubbing in patients with Tourette syndrome: Three case reports. Eye rubbing is an important risk factor for keratoconus progression. Tourette syndrome (TS) is a neurological disorder, and approximately 50% of individuals with TS exhibit obsessive-compulsive behaviors including eye rubbing. We report the effects of corneal cross-linking (CXL) on the progression of keratoconus combined with psychiatric treatment for 3 patients

Full Text available with Trip Pro

2019 Medicine

120. A hexanucleotide repeat modifies expressivity of X-linked dystonia parkinsonism. (PubMed)

A hexanucleotide repeat modifies expressivity of X-linked dystonia parkinsonism. X-linked dystonia parkinsonism (XDP) is a neurodegenerative movement disorder caused by a single mutation: SINE-VNTR-Alu (SVA) retrotransposon insertion in TAF1. Recently, a (CCCTCT)n repeat within the SVA insertion has been reported as an age-at-onset (AAO) modifier in XDP. Here we investigate the role of this hexanucleotide repeat in modifying expressivity of XDP.We genotyped the hexanucleotide repeat in 355 XDP (...) expressivity in XDP. RN-dependent TAF1 repression and subsequent differences in TAF1 mRNA levels in patients may be potentiated in the brain through somatic variability leading to the neurological phenotype. ANN NEUROL 2019.© 2019 American Neurological Association.

2019 Annals of Neurology

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>